These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 18764725)

  • 1. Emerging drugs for adrenocortical carcinoma.
    Berruti A; Ferrero A; Sperone P; Daffara F; Reimondo G; Papotti M; Dogliotti L; Angeli A; Terzolo M
    Expert Opin Emerg Drugs; 2008 Sep; 13(3):497-509. PubMed ID: 18764725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.
    Lerario AM; Worden FP; Ramm CA; Hesseltine EA; Stadler WM; Else T; Shah MH; Agamah E; Rao K; Hammer GD
    Horm Cancer; 2014 Aug; 5(4):232-9. PubMed ID: 24849545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update in adrenocortical carcinoma.
    Fassnacht M; Kroiss M; Allolio B
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New perspectives for mitotane treatment of adrenocortical carcinoma.
    Puglisi S; Calabrese A; Basile V; Pia A; Reimondo G; Perotti P; Terzolo M
    Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101415. PubMed ID: 32179008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant mitotane in adrenocortical carcinoma.
    Dickstein G; Shechner C; Nativ O
    N Engl J Med; 2007 Sep; 357(12):1257-8; author reply 1259. PubMed ID: 17891838
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant mitotane in adrenocortical carcinoma.
    Bertherat J; Coste J; Bertagna X
    N Engl J Med; 2007 Sep; 357(12):1256-7; author reply 1259. PubMed ID: 17881760
    [No Abstract]   [Full Text] [Related]  

  • 7. Adjuvant mitotane in adrenocortical carcinoma.
    Lee JE
    N Engl J Med; 2007 Sep; 357(12):1258; author reply 1259. PubMed ID: 17891836
    [No Abstract]   [Full Text] [Related]  

  • 8. Contemporary management of adrenocortical carcinoma.
    Zini L; Porpiglia F; Fassnacht M
    Eur Urol; 2011 Nov; 60(5):1055-65. PubMed ID: 21831516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant mitotane therapy of adrenal cancer - use and controversy.
    Schteingart DE
    N Engl J Med; 2007 Jun; 356(23):2415-8. PubMed ID: 17554125
    [No Abstract]   [Full Text] [Related]  

  • 10. Adrenocortical Carcinoma: Role of Adjuvant and Neoadjuvant Therapy.
    Kenney L; Hughes M
    Surg Oncol Clin N Am; 2023 Apr; 32(2):279-287. PubMed ID: 36925185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a levonorgestrel-releasing intrauterine device for menorrhagia treatment during adjuvant therapy of adrenocortical carcinoma with mitotane.
    Szkodziak PR; Czuczwar P; Woźniak S; Szkodziak F; Paszkowski T
    Ginekol Pol; 2017; 88(10):576-577. PubMed ID: 29192420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant mitotane in adrenocortical carcinoma.
    Machens A; Dralle H
    N Engl J Med; 2007 Sep; 357(12):1258-9; author reply 1259. PubMed ID: 17891837
    [No Abstract]   [Full Text] [Related]  

  • 13. Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma.
    Boilève A; Mathy E; Roux C; Faron M; Hadoux J; Tselikas L; Al Ghuzlan A; Hescot S; Leboulleux S; de Baere T; Lamartina L; Deschamps F; Baudin E
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4698-e4707. PubMed ID: 34143888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.
    Kerkhofs TM; Baudin E; Terzolo M; Allolio B; Chadarevian R; Mueller HH; Skogseid B; Leboulleux S; Mantero F; Haak HR; Fassnacht M
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4759-67. PubMed ID: 24057287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitotane treatment for adrenocortical carcinoma: an overview.
    De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F
    Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma.
    Pape E; Feliu C; Yéléhé-Okouma M; Colling N; Djerada Z; Gambier N; Weryha G; Scala-Bertola J
    Oncologist; 2018 Mar; 23(3):389-390. PubMed ID: 29192018
    [No Abstract]   [Full Text] [Related]  

  • 17. Practical treatment using mitotane for adrenocortical carcinoma.
    Terzolo M; Zaggia B; Allasino B; De Francia S
    Curr Opin Endocrinol Diabetes Obes; 2014 Jun; 21(3):159-65. PubMed ID: 24732405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
    Calabrese A; Basile V; Puglisi S; Perotti P; Pia A; Saba L; Berchialla P; Porpiglia F; Veltri A; Volante M; Reimondo G; Berruti A; Terzolo M
    Eur J Endocrinol; 2019 Jun; 180(6):387-396. PubMed ID: 30991359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel.
    Berruti A; Fassnacht M; Baudin E; Hammer G; Haak H; Leboulleux S; Skogseid B; Allolio B; Terzolo M
    J Clin Oncol; 2010 Aug; 28(23):e401-2; author reply e403. PubMed ID: 20567001
    [No Abstract]   [Full Text] [Related]  

  • 20. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
    Doghman M; Lalli E
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.